Composition for treating a fluid

Abstract
An aggregate composition and process for making the aggregate composition. The aggregate composition includes an insoluble rare earth-containing compound and a polymer binder. The insoluble rare earth-containing compound can include one or more of cerium, lanthanum, or praseodymium. A suitable insoluble cerium-containing compound can be derived from cerium carbonate or a cerium salt. In a specific embodiment, the aggregate composition consists essentially of one or more cerium oxides, the polymer binder and optionally a flow aid. A process for making the composition includes mixing the insoluble rare earth-containing compound with a polymer binder to form a mixture, and subjecting the mixture to mechanical, chemical and/or thermal treatment to adhere the rare earth compound to the polymer binder. The aggregate composition can be used in a variety of fluid treatment applications to remove one or more chemical and biological contaminants in a fluid.
Description
FIELD OF THE INVENTION

The invention relates generally to the field of fluid treatment, and primarily to compositions for treating solutions and gases. In its more particular aspects, the invention relates to aggregate compositions suitable for use in treating aqueous solutions and gases that contain one or more chemical and biological contaminants, and processes for making such aggregate compositions.


BACKGROUND OF THE INVENTION

The purification and filtration of water and other aqueous solutions is necessary for many applications such as the provision of safe portable drinking water, the treatment of feeds, process streams and by-products associated with various industrial processes, and the treatment and handling of municipal waste water. Known methods for purifying aqueous solutions include reverse osmosis, distillation, ion-exchange, chemical adsorption, coagulation, flocculation, and filtering or retention. Many of these purification practices can be costly, energy inefficient and require significant technical know-how and sophistication to implement on both large and small scales. As a result, many advanced fluid purification technologies have had limited application beyond municipal or industrial applications.


Biological contaminants such as bacteria and fungi can be removed from aqueous solutions through ultrafiltration, but viruses are generally too small for filtration to be an effective means of purification. Because filtration is only somewhat effective, treatment with chemical additives tends to be the method of choice to address the presence of such contaminants. Examples of chemical additives include strong oxidizing agents such as chlorine, hydrogen peroxide, ozone or quaternary amine salts, flocculating agents, and precipitation agents. However, the use of chemical additive(s) requires careful administration and monitoring of the treated solutions as well special handling, transport, and storage, rendering them more costly and less desirable for many applications. As a result, simplified means for removing biological contaminants from aqueous solutions is desired.


In addition, with the recent rise in terrorism, governments around the world have become increasingly concerned about the effects of chemical warfare agents, biological agents, industrial chemicals and other toxic materials. Because nations stockpile such materials for both industrial uses and for use as warfare agents, such contaminants represent a hazard to armed forces and civilian populations due to potential exposure through inhalation, absorption, and/or ingestion. As a result, the contamination of ground water and other sources of portable water with chemical and biological contaminants is a primary concern for the military and for municipal governments and utility districts.


Commonly known chemical warfare agents include organosulfur-based compounds such as 2,2′-Dichlorodiethyl sulfide (HD, mustard, mustard gas, S mustard or sulfur mustard), which are known as “blister” or “blistering” agents and can be lethal in high doses. Other chemical warfare agents include organophosphorus-based (“OP”) compounds, such as O-ethyl S-(2-diisopropylamino) ethyl methylphosphonothiolate (VX), 2-Propyl methylphosphonofluoridate (GB or Sarin), and 3,3′-Dimethyl-2-butyl methylphosphonofluoridate (GD or Soman), which are commonly referred to as “nerve” agents because they attack the central nervous system and can cause paralysis and potentially death in a short period of time. Other chemical contaminants include certain industrial chemicals, insecticides and pesticides such as parathion, paraoxon and malathion, which can also have harmful effects.


Methods and materials for decontaminating surfaces exposed to chemical warfare agents are known in the art. Yang et al., “Decontamination of Chemical Warfare Agents”, Chem. Rev. Vol. 92, pp 1729-1743 (1992). These methods and materials tend to function by chemically reacting with and/or adsorbing the chemical warfare agent, but are focused on decontaminating vehicles, equipment, personnel and other surfaces that have been exposed to the agent. Because such methods and materials are not suitable or sufficiently effective at treating chemical warfare agents in solution there remains a need for simplified means for removing and/or detoxifying a broad spectrum of chemical contaminants from aqueous solutions, including, but not limited to, nerve agents, blister agents, pesticides, insecticides and other toxic chemical agents.


Moreover, exposure to chemical and biological contaminants through inhalation is also a concern that has not been adequately addressed. Basic methods that are used to control air quality include filtration, absorption on solid sorbents, electrostatic precipitation, chemical conversion, and treatment with various forms of radiation including heat, ultraviolet light and microwave. Gas filtration methods tend to be limited by the pore size of the filters, and are generally not capable of removing many biological and chemical contaminants. The use of ultra small pore sizes tend to clog due to particulates on the filter producing excessive pressure drop across the filter that is unacceptable for many applications. Electrostatic precipitation operates by imposing a charge on particles and then removing them from a gas stream onto an oppositely charged surface such as on a collection plate. This technique is not well suited for high velocity gas streams, for fluids containing volatile chemical contaminants or for contaminants that are otherwise difficult to charge. Chemical reactions tend to be effective on only small volumes of gas and can require additional processing or handling of the gas to remove undesirable and potentially harmful reagents and byproducts that remain. Heating, although effective for removing many types of biological and chemical contaminants from gases, tends to be ineffective on higher velocity gas streams. Ultraviolet light can be effective but is difficult to implement on larger gas volumes as the light tends to be absorbed by only those contaminants in the portion of the gas stream immediately adjacent the light source.


Adsorption of gases on a sorbent can be effective particularly where the sorbent is specifically matched to the contaminant to be removed from the gas. However, where the specific nature of the contaminant is not known or where the gas stream contains a number of diverse contaminants the use of known sorbents may not adequately purify the gas. As a result, there remains a need for a composition that is capable of removing, deactivating and/or detoxifying a diverse set of biological and chemical contaminants such as bacteria, viruses, nerve agents, blister agents, pesticides insecticides and other toxic chemical agents that may be present in a variety of fluids, including both aqueous solutions and gases.


SUMMARY OF THE INVENTION

In one embodiment, the invention provides an aggregate composition for treating a fluid containing one or more contaminants. The aggregate composition includes an insoluble rare earth-containing compound and a polymer binder.


The polymer binder can be less than about 15% by weight of the composition, in some cases less than about 10% by weight, and in still other cases less than about 8% by weight of the composition. The polymer binder can include one or more polymers selected from the group consisting of thermosetting polymers, thermoplastic polymers, elastomeric polymers, cellulosic polymers and glasses. Where the polymer binder comprises an ethylene-vinyl copolymer, the insoluble rare earth-containing compound consists essentially of an anhydrous insoluble rare earth-containing compound.


The insoluble rare earth-containing compound can include any insoluble rare earth compound but can specifically include one or more of cerium, lanthanum, or praseodymium. In some embodiments, the insoluble rare earth-containing compound can include a cerium-containing compound derived from thermal decomposition of a cerium carbonate or the decomposition of a cerium oxalate. In other embodiments, the insoluble rare earth-containing compound can include a cerium-containing compound derived from precipitation of a cerium salt. In other embodiments, the insoluble rare earth-containing compound comprises a cerium oxide. In a more specific embodiment, the aggregate composition consists essentially of one or more cerium oxides, the polymer binder, and optionally, a flow aid. The insoluble rare earth-containing compound can include particulates adhered to an outer surface of the polymer binder.


The aggregate composition can comprise aggregated particulates having a mean surface area of at least about 1 m2/g, in some cases at least about 5 m2/g, and in still other cases, at least about 25 m2/g. The aggregate composition can comprise aggregated particulates having a mean aggregate size of at least about 1 μm. The aggregate composition has an adsorption capacity for removing arsenic from an aqueous solution of at least about 50 mg/g of the aggregate composition. In some cases, the adsorption capacity of the composition for removing arsenic from an aqueous solution is at least about 60 mg/g of the aggregate composition, and in other cases, at least about 70 mg/g.


In another aspect of the invention, a process for making an aggregate composition for treating a fluid containing one or more contaminants is provided. The process includes an initial step of mixing an insoluble rare earth-containing compound with a polymer binder to form a mixture.


The mixture is subjected to one or more of a mechanical, chemical and thermal treatment to adhere the insoluble rare earth-containing compound to the polymer binder. Mechanical treatments can include compacting, compressing, pressing, mixing, extruding and applying vibration or waves to the mixture. Chemical treatments can include one or more of chemical conversion and use of an adhesive. Thermal treatments can include heating the mixture to an elevated temperature, and allowing the mixture to cool to form an aggregate composition. In some embodiments, the elevated temperature is a temperature below the melting point of the polymer binder at which the polymer binder is malleable or tacky and the insoluble rare earth-containing compound adheres to the polymer binder. In an embodiment where the insoluble rare earth-containing compound comprises particulates, the particulates can adhere to the outer surface of the polymer binder.


The insoluble rare earth-containing compound can comprise particulates that adhere to an outer surface of the polymer binder. Optionally, the process can include compressing a heated mixture of insoluble rare earth-containing compound and polymer binder.


An optional step can include reducing the size of the aggregate composition. Size reduction can be achieved by one or more of cutting, crushing, milling, and sieving the aggregate composition.


The polymer binder can be less than about 15% by weight of the composition, in some cases less than about 10% by weight, and in still other cases less than about 8% by weight of the composition. The polymer binder can include one or more polymers selected from the group consisting of thermosetting polymers, thermoplastic polymers, elastomeric polymers, cellulosic polymers and glasses. Where the polymer binder comprises an ethylene-vinyl copolymer, the insoluble rare earth-containing compound consists essentially of an anhydrous insoluble rare earth-containing compound.


The polymer binder can be a solid. In some embodiments, the polymer binder comprises one or more of fibers, particulates, aggregates of fibers and or particulates, and mixtures of the same. The insoluble rare earth-containing compound can include particulates having a mean particle size of greater than about 1 nm. The insoluble rare earth-containing compound can include any insoluble rare earth compound but can specifically include one or more of cerium, lanthanum, or praseodymium. In some embodiments, the insoluble rare earth-containing compound can include a cerium-containing compound derived from thermal decomposition of a cerium carbonate. In other embodiments, the insoluble rare earth-containing compound can include a cerium-containing compound derived from precipitation of a cerium salt. In other embodiments, the insoluble rare earth-containing compound comprises a cerium oxide. In a more specific embodiment, the aggregate composition consists essentially of one or more cerium oxides, the polymer binder, and optionally, a flow aid.







DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Illustrative embodiments of the invention are described below. In the interest of clarity, not all features of an actual embodiment are described in this specification. It will of course be appreciated that in the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which will vary from one implementation to another. Moreover it will be appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking for those of ordinary skill in the art-having the benefit of this disclosure.


It will be understood that an aggregate composition as described herein can be used to remove, deactivate and/or detoxify one or more chemical and biological contaminants in an aqueous solution or gas. Examples of solutions that can be treated with the compositions described herein include solutions in portable-water systems, in waste water treatment systems, and in feed, process or waste streams of various industrial processes, among others. Moreover, there is a need to treat gases containing such contaminants in open environments such as on the battlefield, in enclosed spaces such as within buildings or similar structures, within vehicles such as airplanes, space craft, ships or military vehicles, and wherever such contaminants may be found. The described compositions can be used to remove chemical and biological contaminants from aqueous solutions and gases having diverse volume and flow rate characteristics and can be applied in a variety of fixed, mobile and portable applications. While portions of the disclosure herein describe the removal of contaminants from water, such references are illustrative and are not to be construed as limiting.


As used herein, “one or more of” and “at least one of” when used to preface several elements or classes of elements such as X, Y and Z or X1-Xn, Y1-Yn, and Z1-Zn, is intended to refer to a single element selected from X or Y or Z, a combination of elements selected from the same class (such as X1 and X2), as well as a combination of elements selected from two or more classes (such as Y1 and Zn).


The terminology “remove” or “removing” includes the sorption, precipitation, conversion, and killing of pathogenic and other microorganisms, such as bacteria, viruses, fungi and protozoa and of chemical contaminants that may be present in the solution or gas. The terms “deactivate” or “deactivation”, “de-toxify” or “detoxification” and “neutralize” include removing a biological or chemical contaminant from a fluid or rendering it non-pathogenic or benign to humans or other animals such as for example by killing the microorganism or converting the chemical agent into a non-toxic form or species.


The terms “biological contaminant”, “microbe”, “microorganism”, and the like include bacteria, fungi, protozoa, viruses, algae and other biological entities and pathogenic species that can be found in aqueous solutions. Specific non-limiting examples of biological contaminants can include bacteria such as Escherichia coli, Streptococcus faecalis, Shigella spp, Leptospira, Legimella pneumophila, Yersinia enterocolitica, Staphylococcus aureus, Pseudornonas aeruginosa, Klebsiella terrigena, Bacillus anthracis, Vibrio cholerae and Salmonella typhi, viruses such as hepatitis A, notoviruses, rotaviruses, and enteroviruses, protozoa such as Entamoeba histolytica, Giardia, Cryptosporidium parvum and others. Biological contaminants can also include various species such as fungi or algae that are generally non-pathogenic but which are advantageously removed. How such biological contaminants came to be present in the solution or gas, either through natural occurrence or through intentional or unintentional contamination, is non-limiting of the invention.


The term “chemical contaminant” or “chemical agent” includes known chemical warfare agents and industrial chemicals and materials such as pesticides, insecticides and fertilizers. In some embodiments, the chemical contaminant can include one or more of an organosulfur agent, an organophosphorous agent or a mixture thereof. Specific non-limiting examples of such agents include o-alkyl phosphonofluoridates, such as sarin and soman, o-alkyl phosphoramidocyanidates, such as tabun, o-alkyl, s-2-dialkyl aminoethyl alkylphosphonothiolates and corresponding alkylated or protonated salts, such as VX, mustard compounds, including 2-chloroethylchloromethylsulfide, bis(2-chloroethyl)sulfide, bis(2-chloroethylthio)methane, 1,2-bis(2-chloroethylthio)ethane, 1,3-bis(2-chloroethylthio)-n-propane, 1,4-bis(2-chloroethylthio)-n-butane, 1,5-bis(2-chloroethylthio)-n-pentane, bis(2-chloroethylthiomethyl)ether, and bis(2-chloroethylthioethyl)ether, Lewisites, including 2-chlorovinyldichloroarsine, bis(2-chlorovinyl)chloroarsine, tris(2-chlorovinyl)arsine, bis(2-chloroethyl)ethylamine, and bis(2-chloroethyl)methylamine, saxitoxin, ricin, alkyl phosphonyldifluoride, alkyl phosphonites, chlorosarin, chlorosoman, amiton, 1,1,3,3,3,-pentafluoro-2-(trifluoromethyl)-1-propene, 3-quinuclidinyl benzilate, methylphosphonyl dichloride, dimethyl methylphosphonate, dialkyl phosphoramidic dihalides, alkyl phosphoramidates, diphenyl hydroxyacetic acid, quinuclidin-3-ol, dialkyl aminoethyl-2-chlorides, dialkyl aminoethane-2-ols, dialkyl aminoethane-2-thiols, thiodiglycols, pinacolyl alcohols, phosgene, cyanogen chloride, hydrogen cyanide, chloropicrin, phosphorous oxychloride, phosphorous trichloride, phosphorus pentachloride, alkyl phosphorous oxychloride, alkyl phosphites, phosphorous trichloride, phosphorus pentachloride, alkyl phosphites, sulfur monochloride, sulfur dichloride, and thionyl chloride.


Non-limiting examples of industrial chemical and materials that may be effectively treated with the compositions described herein include materials that have anionic functional groups such as phosphates, sulfates and nitrates, and electro-negative functional groups, such as chlorides, fluorides, bromides, ethers and carbonyls. Specific non-limiting examples can include acetaldehyde, acetone, acrolein, acrylamide, acrylic acid, acrylonitrile, aldrin/dieldrin, ammonia, aniline, arsenic, atrazine, barium, benzidine, 2,3-benzofuran, beryllium, 1,1′-biphenyl, bis(2-chloroethyl)ether, bis(chloromethyl)ether, bromodichloromethane, bromoform, bromomethane, 1,3-butadiene, 1-butanol, 2-butanone, 2-butoxyethanol, butraldehyde, carbon disulfide, carbon tetrachloride, carbonyl sulfide, chlordane, chlorodecone and mirex, chlorfenvinphos, chlorinated dibenzo-p-dioxins (CDDs), chlorine, chlorobenzene, chlorodibenzofurans (CDFs), chloroethane, chloroform, chloromethane, chlorophenols, chlorpyrifos, cobalt, copper, creosote, cresols, cyanide, cyclohexane, DDT, DDE, DDD, DEHP, di(2-ethylhexyl)phthalate, diazinon, dibromochloropropane, 1,2-dibromoethane, 1,4-dichlorobenzene, 3,3′-dichlorobenzidine, 1,1-dichloroethane, 1,2-dichloroethane, 1,1-dichloroethene, 1,2-dichloroethene, 1,2-dichloropropane, 1,3-dichloropropene, dichlorvos, diethyl phthalate, diisopropyl methylphosphonate, di-n-butylphtalate, dimethoate, 1,3-dinitrobenzene, dinitrocresols, dinitrophenols, 2,4- and 2,6-dinitrotoluene, 1,2-diphenylhydrazine, di-n-octylphthalate (DNOP), 1,4-dioxane, dioxins, disulfoton, endosulfan, endrin, ethion, ethylbenzene, ethylene oxide, ethylene glycol, ethylparathion, fenthions, fluorides, formaldehyde, freon 113, heptachlor and heptachlor epoxide, hexachlorobenzene, hexachlorobutadiene, hexachlorocyclohexane, hexachlorocyclopentadiene, hexachloroethane, hexamethylene diisocyanate, hexane, 2-hexanone, HMX (octogen), hydraulic fluids, hydrazines, hydrogen sulfide, iodine, isophorone, malathion, MBOCA, methamidophos, methanol, methoxychlor, 2-methoxyethanol, methyl ethyl ketone, methyl isobutyl ketone, methyl mercaptan, methylparathion, methyl t-butyl ether, methylchloroform, methylene chloride, methylenedianiline, methyl methacrylate, methyl-tert-butyl ether, mirex and chlordecone, monocrotophos, N-nitrosodimethylamine, N-nitrosodiphenyl amine, N-nitrosodi-n-propylamine, naphthalene, nitrobenzene, nitrophenols, perchloroethylene, pentachlorophenol, phenol, phosphamidon, phosphorus, polybrominated biphenyls (PBBs), polychlorinated biphenyls (PCBs), polycyclic aromatic hydrocarbons (PAHs), propylene glycol, phthalic anhydride, pyrethrins and pyrethroids, pyridine, RDX (cyclonite), selenium, styrene, sulfur dioxide, sulfur trioxide, sulfuric acid, 1,1,2,2-tetrachloroethane, tetrachloroethylene, tetryl, thallium, tetrachloride, trichlorobenzene, 1,1,1-trichloroethane, 1,1,2-trichloroethane, trichloroethylene (TCE), 1,2,3-trichloropropane, 1,2,4-trimethylbenzene, 1,3,5-trinitrobenzene, 2,4,6-trinitrotoluene (TNT), vinyl acetate, and vinyl chloride.


In one embodiment of the invention, an aggregate composition is provided for treating a fluid containing one or more chemical and biological contaminants. The aggregate composition comprises an insoluble rare earth-containing compound and a polymer binder.


As used herein, “insoluble” is intended to refer to materials that are insoluble in water, or at most, are sparingly soluble in water under standard conditions of temperature and pressure.


The composition can comprise less than or more than 10.01% by weight of the insoluble rare earth-containing compound. The insoluble rare earth-containing compound can constitute more than about 11%, more than about 12% or more than about 15% by weight of the aggregate composition. In some cases, a higher concentration of rare earth-containing compounds may be desired. Depending on the application and the nature of other components in the composition, the composition can be at % least about 20%, in other cases at least about 50%, in still others at least about 75%, and in yet still others more than 95%, by weight of an insoluble rare earth-containing compound.


The insoluble rare earth-containing compound can include one or more of the rear earths including lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium erbium, thulium, ytterbium and lutetium. In some embodiments, the insoluble rare-earth containing compound can comprise one or more of cerium, lanthanum, or praseodymium. Insoluble rare earth-containing compounds are available commercially and may be obtained from any source or through any process known to those skilled in the art. The composition need not include a single rare earth-containing compound but can include two or more insoluble rare earth-containing compounds. Such compounds can contain the same or different rare earth elements and can contain mixed valence or oxidation states. By way of example, when the insoluble rare earth-containing compound comprises a cerium oxide, the aggregate composition can comprise one or more cerium oxides such as CeO2 (IV) and Ce2O3 (III).


In an embodiment where the insoluble rare earth-containing compound comprises a cerium-containing compound, the cerium-containing compound can be derived from precipitation of a cerium salt. In another embodiment, an insoluble cerium-containing compound can be derived from a cerium carbonate or a cerium oxalate. More specifically, a high surface area insoluble cerium-containing compound can be prepared by thermally decomposing a cerium carbonate or oxalate at a temperature between about 100° C. and about 350° C. in a furnace in the presence of air. The temperature and pressure conditions may be altered depending on the composition of the cerium containing starting material and the desired physical properties of the insoluble rare earth-containing compound. The reaction may be summarized as:

Ce2(CO3)3+½O2→2CeO2+3CO2

The product may be acid treated and washed to remove remaining carbonate. Thermal decomposition processes for producing cerium oxides having various features are described in U.S. Pat. No. 5,897,675 (specific surface areas), U.S. Pat. No. 5,994,260 (pores with uniform lamellar structure), U.S. Pat. No. 6,706,082 (specific particle size distribution), and U.S. Pat. No. 6,887,566 (spherical particles), and such descriptions are incorporated herein by reference. Cerium carbonate and materials containing cerium carbonate are commercially available and may be obtained from any source known to those skilled in the art.


In embodiments where the insoluble rare earth-containing compound comprises a cerium oxide, the insoluble rare earth-containing compound can include a cerium oxide such as CeO2. In a particular embodiment, the aggregate composition can consists essentially of one or more cerium oxides, the polymer binder, and optionally, a flow aid.


The insoluble rare earth-containing compound can be present in the aggregate composition in the form of one or more of a granule, crystal, crystallite, particle or other particulate, referred to generally herein as a “particulate.” The particulates of the insoluble rare earth-containing compounds can have a mean particle size of at least about 0.5 nm ranging up to about 1 μm or more. Specifically, such particulates can have a mean particle size of at least about 0.5 nm, more than about 1 nm, more particularly at least about 5 nm, and still more particularly at least about 10 nm. In other embodiments, the particulates can have mean particle sizes of at least about 100 nm, specifically at least about 250 nm, more specifically at least about 500 nm, and still more specifically at least about 1 μm.


To promote interaction of the insoluble-rare earth-containing compound with a contaminant in a solution or gas, the aggregate composition can comprise aggregated particulates of the insoluble rare earth-containing compound having a mean surface area of at least about 1 m2/g. Depending upon the application, higher surface areas may be desired. Specifically, the particulates can have a surface area of at least about 5 m2/g, in other cases more than about 10 m2/g, and in still other cases more than about 25 m2/g. Where higher surface areas are desired, the particulates can have a surface area of more than about 70 m2/g, in other cases more than about 85 m2/g, in still other cases more than 115 m2/g, and in yet other cases more than about 160 m2/g. In addition, it is envisioned that particulates with higher surface areas will be effective. One skilled in the art will recognize that in applications where the solution or gas flows through the composition, the surface area of the composition will impact the fluid dynamics of the fluid with the aggregate composition. As a result, one may need to balance benefits that are derived from increased surface areas with disadvantages such as pressure drop that may occur.


A polymer binder is included in the composition for forming an aggregate having desired size, structure, density, porosity and fluid properties. In some embodiments, the polymer binder can comprise one or more of fibers, particulates, aggregates of fibers and or particulates, and mixtures of the same. A suitable polymer binder can include any polymeric material that will bind and/or support the insoluble rare earth-containing compound under conditions of use. Suitable polymeric binders will include both naturally occurring and synthetic polymers, as well as synthetic modifications of such polymers. One skilled in the art will recognize that the selection of the polymer binder material will depend on such factors as the composition components, the properties of such components, their binding characteristics, the characteristics of the final composition and the intended method of use.


In general, polymers melting between about 50° C. and about 500° C., more particularly, between about 75° C. and about 350° C., even more particularly between about 80° C. and about 200° C., are suitable for use in aggregating the components of the composition. Non-limiting examples can include polyolefins that soften or melt in the range from about 85° C. to about 180° C., polyamides that soften or melt in the range from about 200° C. to about 300° C., and fluorinated polymers that soften or melt in the range from about 300° C. to about 400° C. The melting point of the polymer binder will preferably not exceed the sintering temperature of the selected insoluble rare earth-containing compound.


Such polymer materials will generally be included in the aggregate composition in amounts ranging from about 0 wt % to about 90 wt %, based upon the total weight of the composition. In some embodiments, the polymer binder will be present in an amount less than about 15% by weight of the composition. More specifically, the polymer binder may be less than about 10%, and in other embodiments, less than about 8% by weight of the composition.


Depending upon the desired properties of the composition, polymer binders can include one or more polymers generally categorized as thermosetting, thermoplastic, elastomer, or a combination thereof as well as cellulosic polymers and glasses. Suitable thermosetting polymers include, but are not limited to, polyurethanes, silicones, fluorosilicones, phenolic resins, melamine resins, melamine formaldehyde, and urea formaldehyde. Suitable thermoplastics can include, but are not limited to, nylons and other polyamides, polyethylenes, including LDPE, LLDPE, HDPE, and polyethylene copolymers with other polyolefins, polyvinylchlorides (both plasticized and unplasticized), fluorocarbon resins, such as polytetrafluoroethylene, polystyrenes, polypropylenes, cellulosic resins such as cellulose acetate butyrates, acrylic resins, such as polyacrylates and polymethylmethacrylates, thermoplastic blends or grafts such as acrylonitrile-butadiene-styrenes or acrylonitrile-styrenes, polycarbonates, polyvinylacetates, ethylene vinyl acetates, polyvinyl alcohols, polyoxymethylene, polyformaldehyde, polyacetals, polyesters, such as polyethylene terephthalate, polyether ether ketone, and phenol-formaldehyde resins, such as resols and novolacs. Suitable elasomers can include, but are not limited to, natural and/or synthetic rubbers, like styrene-butadiene rubbers, neoprenes, nitrile rubber, butyl rubber, silicones, polyurethanes, alkylated chlorosulfonated polyethylene, polyolefins, chlorosulfonated polyethylenes, perfluoroelastomers, polychloroprene (neoprene), ethylene-propylene-diene terpolymers, chlorinated polyethylene, fluoroelastomers, and ZALAK™ (Dupont-Dow elastomer). In a specific embodiment where the polymer binder comprises an ethylene vinyl copolymer, the insoluble rare earth-containing compound consists essentially of an anhydrous rare earth-containing compound. Those of skill in the art will realize that some of the thermoplastics listed above can also be thermosets depending upon the degree of cross-linking, and that some of each may be elastomers depending upon their mechanical properties. The categorization used above is for ease of understanding and should not be regarded as limiting or controlling.


Cellulosic polymers can include naturally occurring cellulose such as cotton, paper and wood and chemical modifications of cellulose. In a specific embodiment, the insoluble rare earth-containing compound can be mixed with paper fibers or incorporated directly into paper pulp for forming a paper-based filter comprising the insoluble rare earth-containing compound.


Polymer binders can also include glass materials such as glass fibers, beads and mats. Glass solids may be mixed with particulates of an insoluble rare earth-containing compound and heated until the solids begin to soften or become tacky so that the insoluble rare earth-containing compound adheres to the glass. Similarly, extruded or spun glass fibers may be coated with particles of the insoluble rare earth-containing compound while the glass is in a molten or partially molten state or with the use of adhesives. Alternatively, the glass composition may be doped with the insoluble rare earth-containing compound during manufacture. Techniques for depositing or adhering insoluble rare earth-containing compounds to a substrate material are described in U.S. Pat. No. 7,252,694 and other references concerning glass polishing. For example, electro-deposition techniques and the use of metal adhesives are described in U.S. Pat. No. 6,319,108 as being useful in the glass polishing art. The descriptions of such techniques are incorporated herein by reference.


In some applications, water-soluble glasses such as are described in U.S. Pat. Nos. 5,330,770, 6,143,318 and 6,881,766, may be an appropriate polymer binder. The descriptions of such glasses in the noted references are incorporated herein by reference. In other applications, materials that swell through fluid absorption including but not limited to polymers such as synthetically produced polyacrylic acids, and polyacrylamides and naturally-occurring organic polymers such as cellulose derivatives may also be used. Biodegradable polymers such as polyethylene glycols, polylactic acids, polyvinylalcohols, co-polylactideglycolides, and the like may also be used as the polymer binder.


Where it is desirable to regenerate the composition through sterilization, the selected polymer binder should be stable under sterilization conditions and should be otherwise compatible with the intended sterilization method. Specific non-limiting examples of polymer binders that are suitable for sterilization methods that involve exposure to high temperatures include cellulose nitrate, polyethersulfone, nylon, polypropylene, polytetrafluoroethylene, and mixed cellulose esters. Compositions prepared with these binders can be autoclaved when the prepared according to known standards. The aggregate composition can be stable to steam sterilization or autoclaving as well as to chemical sterilization through contact with oxidative or reductive chemical species, as a combination of sterilization methods may be required for efficient and effective regeneration. In an embodiment where sterilization includes the electrochemical generation of an oxidative or reductive chemical species, the electrical potential necessary to generate said species can be attained by using the composition as one of the electrodes. For example, a composition that contains a normally insulative polymer binder can be rendered conductive through the inclusion of a sufficiently high level of conductive particles such as granular activated carbon, carbon black, or metallic particles. Alternatively, if the desired level of carbon or other particles is not sufficiently high to render an otherwise insulative polymer conductive, an intrinsically conductive polymer may included in the binder material.


Optional components that are suitable for use in the aggregate composition can include one or more of soluble rare earth-containing compounds, decontamination agents, biocidal agents, adsorbents, flow aids, non-polymer binders and substrates, and the like. Such optional components may be included in the aggregate composition depending on the intended utility and/or the desired characteristics of the composition.


Optional soluble rare earth-containing compounds can have different activities and effects. By way of example, some soluble rare earth-containing compounds have been recognized as having a bacteriostatic or antimicrobial effect. Cerium chloride, cerium nitrate, anhydrous ceric sulfate, and lanthanum chloride are described as having such activity in “The Bacteriostatic Activity of Cerium, Lanthanum, and Thallium”, Burkes et al., Journal of Bacteriology, 54:417-24 (1947). Similarly, the use of soluble cerium salts such as cerium nitrates, cerous acetates, cerous sulfates, cerous halides and their derivatives, and cerous oxalates are described for use in burn treatments in U.S. Pat. No. 4,088,754, such descriptions being incorporated herein by reference. Other soluble rare earth-containing compounds, whether organic or inorganic in nature, may impart other desirable properties to the compositions and may optionally be used.


Optional decontamination agents may include materials that are capable of removing or detoxifying chemical contaminants from various surfaces. Non-limiting examples of decontamination agents that may be suitable include transition metals and alkaline metals as described in U.S. Pat. No. 5,922,926, polyoxometallates as described in U.S. Patent Application Publication No. 2005/0159307 A1, aluminum oxides as described in U.S. Pat. Nos. 5,689,038 and 6,852,903, quaternary ammonium complexes as described in U.S. Pat. No. 5,859,064, zeolites as described in U.S. Pat. No. 6,537,382, and enzymes as described in U.S. Pat. No. 7,067,294. The descriptions of these decontamination agents in the noted references are incorporated herein by reference.


Biocidal agents can optionally be included for targeting biological contaminants in a solution or gas. Materials that may be suitable for use as biocidal agents include but are not limited to alkali metals, alkaline earth metals, transition metals, actinides, and derivatives and mixtures thereof. Specific non-limiting examples of secondary biocidal agents include elemental or compounds of silver, zinc, copper, iron, nickel, manganese, cobalt, chromium, calcium, magnesium, strontium, barium, boron, aluminum, gallium, thallium, silicon, germanium, tin, antimony, arsenic, lead, bismuth, scandium, titanium, vanadium, yttrium, zirconium, niobium, molybdenum, technetium, ruthenium, rhodium, palladium, cadmium, indium, hafnium, tantalum, tungsten, rhenium, osmium, iridium, platinum, gold, mercury, thallium, thorium, and the like. Derivatives of such agents can include acetates, ascorbates, benzoates, carbonates, carboxylates, citrates, halides, hydroxides, gluconates, lactates, nitrates, oxides, phosphates, propionates, salicylates, silicates, sulfates, sulfadiazines, and combinations thereof. When the aggregate composition optionally comprises a titanium-containing compound such as a titanium oxide, the weight ratio of the titanium-containing compound to the insoluble rare earth-containing compound is less than about 2:1. When the aggregate composition optionally comprises an aluminum-containing compound, the weight ratio of the aluminum-containing compound to the insoluble rare earth-containing compound is less than about 10:1. When one or more of the components of the aggregate composition is to be sintered, the composition will contain no more than two elements selected from the group consisting of yttrium, scandium, and europium. In an embodiment that includes an optional biocide agent selected from the group consisting of transition metals, transition metal oxides and transition metal salts, the aggregate composition will comprise less than about 0.01% by weight of a mixture of silver and copper metal nanoparticles.


Other materials that may be suitable for use as biocidal agents include organic agents such as quaternary ammonium salts as described in U.S. Pat. No. 6,780,332, and organosilicon compounds such as are described in U.S. Pat. No. 3,865,728. Other organic materials and their derivatives that are known to deactivate biological contaminants may also be used. By way of example, polyoxometalates are described in U.S. Pat. No. 6,723,349 as being effective at removing biological contaminants from fluids. This patent references M. T. in Heteropoly and Isopoly Oxometalales, Springer Verlag, 1983, and Chemical Reviews, vol. 98, No. 1, pp. 1-389, 1998, as describing examples of effective polyoxometalates. The descriptions of these organic biocidal agents in the noted references are incorporated herein by reference.


The aggregate composition may optionally comprise one or more flow aids. Flow aids are used in part to improve the fluid dynamics of a fluid over or through the aggregate composition, to prevent separation of components of the aggregate composition, prevent the settling of fines, and in some cases to hold the aggregate composition in place. Suitable flow aids can include both organic and inorganic materials. Inorganic flow aids can include ferric sulfate, ferric chloride, ferrous sulfate, aluminum sulfate, sodium aluminate, polyaluminum chloride, aluminum trichloride, silicas, diatomaceous earth and the like. Organic flow aids can include organic flocculents known in the art such as polyacrylamides (cationic, nonionic, and anionic), EPI-DMA's (epichlorohydrin-dimethylamines), DADMAC's (polydiallydimethyl-ammonium chlorides), dicyandiamide/formaldehyde polymers, dicyandiamide/amine polymers, natural guar, etc. When present, the flow aid can be mixed with the insoluble rare earth-containing compound and polymer binder during the formation of the aggregate composition. Alternatively, particulates of the aggregate composition and of the flow aid can be mixed to yield a physical mixture with the flow aid dispersed uniformly throughout the mixture. In yet another alternative, the flow aid can be disposed in one or more distinct layers upstream and downstream of the aggregate composition. When present, flow aids are generally used in low concentrations of less than about 20%, in some cases less than 15%, in other cases less than 10%, and in still other cases less than about 8% by weight of the aggregate composition.


Other optional components can include various inorganic agents including ion-exchange materials such as synthetic ion exchange resins, activated carbons, zeolites (synthetic or naturally occurring), minerals and clays such as bentonite, smectite, kaolin, dolomite, montmorillinite and their derivatives, metal silicate materials and minerals such as of the phosphate and oxide classes. In particular, mineral compositions containing high concentrations of calcium phosphates, aluminum silicates, iron oxides and/or manganese oxides with lower concentrations of calcium carbonates and calcium sulfates are suitable. These materials may be calcined and processed by a number of methods to yield mixtures of varying compositions.


Other optional components of the aggregate composition include additives, such as particle surface modification additives, coupling agents, plasticizers, fillers, expanding agents, fibers, antistatic agents, initiators, suspending agents, photosensitizers, lubricants, wetting agents, surfactants, pigments, dyes, UV stabilizers, and suspending agents. The amounts of these materials are selected to provide the properties desired.


The aggregate composition can be used to remove, deactivate or detoxify chemical and biological contaminants in a solution or gas by contacting the fluid with the composition. Those familiar with the art of fluid treatment will understand that the components, physical dimensions and shape of the aggregate composition may be manipulated for different applications and that variations in these variables can alter flow rates, back-pressure, and the activity of the composition for treating certain contaminants. As a result, the size, form and shape of the aggregate composition can vary considerably depending on the intended method of use. In an embodiment where the aggregate composition is used to treat an aqueous solution containing arsenic, the aggregate composition can have an adsorption capacity for removing arsenic from the solution of at least about 50 mg of arsenic per gram of the aggregate composition. In some cases the adsorption capacity will be at least about 60 mg/g and in other cases at least about 70 mg/g. The adsorption capacity is believed to be in part dependent on the surface area of the insoluble rare earth-containing compound used to prepare the aggregate composition and of the resulting the aggregate composition.


The aggregate composition can be formed though one or more of mixing, extrusion, molding, heating, calcining, sintering, pressing, compaction, the use adhesives and/or other techniques known in the art. In embodiments where it is desired that the aggregate composition have higher surface areas, sintering is less desired. The use of the polymer binder enables the production of an aggregate composition of sufficient size, structure and durability for use in the treatment of solutions and gases. The combination of the polymer binder and the insoluble rare earth-containing compound produces an aggregate composition that has elevated activity for decontaminating fluids without imposing a substantial pressure drop on the treated fluid.


The aggregate composition can comprise a flowable particulate, granule, bead, pellet, powder, fiber, or similar form. Such particulates can have a mean particle size of at least about 1 μm, specifically at least about 5 μm, more specifically at least about 10 μm, and still more specifically at least about 25 μm. In other embodiments, the aggregate will have a mean particle size of at least about 0.1 mm, specifically at least about 0.5 mm, more specifically at least about 1 mm, still more specifically at least about 2 mm, and yet still more specifically more than 5.0 mm. The aggregate composition can be crushed, cut, chopped or milled and then sieved to obtain a desired particle size. Such flowable particulates can be used in fixed or fluidized beds or reactors, stirred reactors or tanks, distributed in particulate filters, encapsulated or enclosed within membranes, mesh, screens, filters or other fluid permeable, structures, deposited on filter substrates, and may further be formed into a desired shape such as a sheet, film, mat or monolith for various applications.


In addition, the aggregate composition can be incorporated into or coated onto a filter substrate. Filter substrates can include polymer and non-polymer binder materials as described herein and materials such as ceramics, metals, carbons, and the like. Filler substrates can be made from particulates, fibers, sheets, films and combinations of the same. The structure of a filter substrate will vary depending upon the application but can include any fluid permeable structure having a desired shape and physical dimensions suitable for the conditions of use. Non-limiting examples include mesh, screens, films, sheets, tubes, honeycombed structures, monoliths and blocks of various shapes including cylinders and toroids.


In another embodiment, the invention provides a process for making an aggregate composition for treating a fluid containing one or more contaminants. The process includes the step of mixing an insoluble rare earth-containing compound with a polymer binder to form a mixture. The insoluble rare earth-containing compound and polymer binder materials have been described in detail above. In a more specific embodiment, the insoluble rare earth-containing compound comprises a high surface area particulate of an insoluble cerium-containing compound, more particularly, the product of a calcined cerium carbonate. Specific examples of the polymer binders that may be mixed with the insoluble rare earth-containing compound include polyolefins, cellulose acetate, acrylonitrile-butadiene-styrene, PTFE, paper fibers, glass fibers or beads, and adhesive polymers. The polymer binder should be selected so as not to have a melting point that exceeds the sintering temperature of the selected insoluble rare earth-containing compound, as sintering of the insoluble rare earth-containing compound can reduce the surface area of the final aggregate composition.


Techniques and equipment known in the art for mixing particulates and fibers can be used to mix the components. The components are subjected to mixing for a period of time sufficient to yield a relatively homogeneous mixture. Moreover, to ensure a more uniform distribution of the insoluble rare earth-containing compound throughout the aggregate composition, in embodiments where the mixture is to be subjected to a heat treatment, it is preferred that the components be thoroughly mixed prior to heating.


The mixture is subjected to one or more of a mechanical, chemical and thermal treatment to adhere the insoluble rare earth-containing compound to the polymer binder. Mechanical treatments can include compacting, compressing, pressing, mixing, extruding and subjecting the mixture to vibration or waves. Compression of the mixture can occur prior, during or after the mixture is heated depending on the desired properties of the aggregate composition. The mixture can be compressed in a press, test cylinder, extruder or other equipment known in the art for compressing or compacting materials into a desired shape or form. The amount of pressure and the duration that such pressure is applied will depend on the selected components, their binding characteristics and the intended use of the aggregate composition. Within limits, the application of higher pressures and/or the application of pressure for longer periods of time are intended to prevent the aggregate composition from degrading or producing fines under conditions of use. Chemical treatments can include one or more of chemical conversion and use of chemical adhesive(s) such as are known in the art. By way of example, a cross linker may be used to promote cross linking of the polymer binder. Thermal treatments can include heating the mixture to an elevated temperature to promote a chemical and/or physical conversion.


In one embodiment, the mixture is heated to a temperature below the melting point of the polymer binder at which the polymer binder softens and becomes malleable or tacky to the touch. The mixture should be heated to a temperature sufficient to ensure that the insoluble rare earth-containing compound will adhere to the polymer binder without fully melting the polymer binder. The specific temperature will depend on the composition of the selected polymer binder. The mixture is then allowed to cool to form an aggregate composition.


In some embodiments, the polymer binder comprises one or more of fibers, particulates, aggregates of fibers or particulates, and mixtures of the same, and the insoluble rare earth-containing compound is adhered to the outer surface of the polymer binder upon treatment of the mixture. Where the insoluble rare earth-containing compound is in the form of a particulate, the aggregate composition product can comprise a matrix of insoluble rare earth-containing particulates adhered to or embedded in the outer surface of the polymer binder.


An optional step can include reducing the size of the aggregate composition. Size reduction can be achieved by techniques known in the art, including one or more of cutting, crushing, milling, and sieving the aggregate composition down to the desired size.


The following examples are provided to demonstrate particular embodiments of the present invention. It should be appreciated by those of skill in the art that the methods disclosed in the examples which follow merely represent exemplary embodiments of the present invention. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments described and still obtain a like or similar result without departing from the spirit and scope of the present invention.


EXAMPLE 1
Particulate Polymer Binder

In this example, aggregates were prepared with Microthene® F (FN50100), a low density polyethylene obtained from Equistar. Microthene® F is an ultra-fine and spherical shaped powder with an average 20 micron particle size, a melt index of 23 g/10 min, and a melting range of 92.0° C.-114.5° C. The cerium oxide (CeO2) was obtained from HEFA Rare Earth Canada Company, Ltd.


Physical mixtures were made of the cerium oxide and the polymer in differing compositions (by weight). Each component was weighed and mixed with a laboratory mixer fitted with a paddle attachment set to rotate at ≈160 rpm for approximately 30 minutes to achieve a homogeneous mixture. A Carver test cylinder with an internal diameter of 1.125 inches was heated to temperatures varying from 90° C. to 100° C. Four grams of the ceria/polymer mixture were poured in to the warmed die and pressed to pressures ranging from 3400 psig to 10000 psig. Pressing times varied from 5 to 20 minutes. After the pellets were pressed, they were cut and sieved between an 18×70 mesh to obtain particles on the order of 500 μm. Specific surface areas were measured on a Micromeritics FlowsorbII 2300 single point BET instrument using the manufacturer's prescribed method.


Table 1 details the parameter set.













TABLE 1





Temperature
Pressure





(° C.)
(psig)
Time (min)
% Binder
SSA (m2/g)



















90
3400
5
2.5
107.74


90
10000
20
2.5
88.11


90
3400
20
10
79.01


95
6800
12.5
6.25
107.08


100
3400
5
10



100
10000
5
2.5
102.45


100
3400
20
2.5
92.72


100
10000
20
10
38.67









EXAMPLE 2
Particulate Polymer Binder

In this example set, aggregates were formed with Polifil® RP ABS (acrylonitrile butadiene styrene) terpolymer obtained from The Plastics Group of America. The thermoplastic resin has a melt flow of 4-8 g/10 min and a vicat softening point of 98.9° C.


The ABS was sieved to yield particles that were less than 100 microns, then mixed with cerium oxides, pressed, and sieved following the same procedure from Example 1. The temperature range of the test cylinder was increased to 105° C. to 110° C. All other parameters remained the same. The 4 g pellets were then cut and sieved between an 18×70 mesh to yield an average particle size of 500 μm. Specific Surface Areas were determined as in Example 1.


Arsenic capacity was determined by challenging 10 mg of the prepared aggregate against 500 ml of a 400 ppb arsenic solution. The solution was prepared in NSF water and the pH was adjusted to 7.5. The 500 ml of solution and 10 mg of material were both put in a wide mouth plastic bottle and allowed to tumble for 24 hours. After the 24 hours, the aggregate was filtered and analyzed for arsenic concentration using Agilent's ICP-MS (Inductively coupled plasma mass spectrometer) Model number 7500CE. For each composition, three samples were prepared, tested and analyzed. The reported As Capacity data represents an average of the three samples for each composition.


Table 2 details the parameter set.














TABLE 2





Temperature
Pressure
Time
%
SSA
As(V) Capacity


(° C.)
(psig)
(min)
Binder
(m2/g)
(mg As/g material)




















105
10000
5
10
91.68
1.33


107.5
6800
12.5
6.25
87.46
1.28


105
3400
5
2.5
115.54
4.38


105
10000
20
2.5
112.27


110
3400
5
10
88.4
3.41


105
3400
20
10
114.86
2.95


110
10000
5
2.5
78.42
2.15


110
3400
20
2.5
89.48
4.11


110
10000
20
10
115.41
3.24









EXAMPLE 3
Particulate Polymer Binder with Diatomaceous Earth

In this example, the parameter set from Example 2 was altered only with the addition of diatomaceous earth (DE). The composition of the DE ranged between 1% and 5% (by weight) and all other parameters and procedures remained the same. The 4 g pellets were then cut and sieved between an 18×70 mesh to yield an average particle size of 500 μm. Specific Surface Areas were determined as in the previous Examples.


Table 3 details the parameter set.













TABLE 3





Temperature
Pressure
%

SSA


° C.
(psig)
Binder
% DE
(m2/g)



















110
3400
2.5
5
91


105
10000
2.5
5
75


105
3400
2.5
1
71


107.5
6800
6.25
3
72


110
3400
10
1
88


110
10000
2.5
1
73


105
10000
10
1
83


110
10000
10
5
64


105
3400
10
5
70


107.5
6800
6.25
3
83









EXAMPLE 4

The procedure from the Examples 1-3 was repeated with the cerium oxide and GUR® 2122, an ultra high molecular weight polyethylene obtained from Ticona. The linear polyolefin has a molecular weight of 4.5 MM g/mol, a vicat softening point of 80° C., and particle size on the order of 100 μm.


The temperature of the test cylinder was varied between 60° C. and 10° C., the pressing pressure between 3400 psig and 10,000 psig, and the pressing time between 0.5 to 5 minutes. The 4 g pellets were cut and sieved between an 1.8×70 mesh to yield an average particle size of 500 μm. Specific Surface Areas were determined as in the previous Examples.


Table 4 lists the parameter matrix for this particular example.













TABLE 4





Temperature
Pressure
Time

SSA


(° C.)
(psig)
(min)
% Binder
(m2/g)



















80
6800
2.75
6
82.13


100
10000
5
10
84.02


60
10000
0.5
10


60
3400
0.5
2


100
3400
5
2
118.01


100
3400
0.5
10
87.28


80
6800
2.75
6
90.26


60
3400
5
10


60
10000
5
2


100
10000
0.5
2









EXAMPLE 5
Fibrous Polymer Binder

In this example, aggregates were produced using Short Stuff® Polyethylene pulp obtained from Mini Fibers, Inc. These fibers are a high density fibrillated polyethylene, a thermoplastic with a melting range of 125° C.-136° C., a length of 0.1 mm-0.6 mm and a diameter of 5 μm. The cerium oxide is the same as with the previous examples.


Each component was weighed and mixed with a laboratory mixer fitted with a blade attachment set to rotate at ≈60 rpm for approximately 30 minutes to achieve a homogeneous mixture. The Carver test cylinder with an internal diameter of 1.125 inches was heated to temperatures varying from 70° C. to 115° C. Four grams of the ceria/polymer mixture were poured in to the warmed die and pressed to pressures ranging from 3400 psig to 10,000 psig. Pressing times also varied at this point from 30 to 120 seconds. The 4 g pellets were cut and sieved between an 18×35 mesh to yield minimum particle size of 500 μm. Specific Surface Areas and As Capacity were determined as in Example 2.


Table 5 details the parameter set.















TABLE 5










As(III) Capacity
As(V) Capacity


Temperature
Pressure
Time
%
SSA
(mg As/g
(mg As/g


(° C.)
(psig)
(sec)
Binder
(m2/g)
material)
material)





















115
10000
120
7
81.8
6.22
1.26


115
3400
120
2
105.86
7.51
3.13


92.5
6800
75
4.5
74.91
5.72
1.62


70
10000
120
2
93.17
5.21
1.77


70
3400
120
7
90.19
7.41
2.07


115
10000
30
2
105.86
5.88
1.05


115
3400
30
7
144.81
5.43
1.07


70
10000
30
7
82.77
5.2
2.16


70
3400
30
2
102.85
5.72
2.82


92.5
6800
75
4.5
84.59
7.02
3.39









EXAMPLE 6
Fibrous Polymer Binder with Diatomaceous Earth

The aggregates in this example were prepared with the same material and procedure as in Example 5 with the addition of diatomaceous earth (DE). The composition of the DE ranged between 1% and 5% (by weight), the composition of the binder ranged from 2%-5% (by weight), and the temperature of the Carver test cylinder ranged from 70° C. to 115° C. The pressing pressure and time was held constant at 6800 psig for 1 minute. The 4 g pellets were cut and sieved between an 18×35 mesh to yield minimum particle size of 500 μm. Specific Surface Areas and As Capacity were determined as in Example 2.


Table 6 details the parameter set.














TABLE 6









As(III)







Capacity


Temperature
%

SSA
(mg As/g
As(V) Capacity


(° C.)
Binder
% DE
(m2/g)
material)
(mg As/g material




















70
5
5
61.2
5.41
4.22


115
5
1
80.85
5.39
3.58


115
2
5
89.81
6.20
3.94


92.5
3.5
3
91.61
7.54
3.73


70
5
1
101.64
5.53
4.11


115
2
1
94.62
5.66
3.28


70
2
1
83.76
7.23
3.59


70
2
5
100.72
7.86
2.98


92.5
3.5
3
65.11
5.81
3.49


115
5
5
58.32
7.56
3.08









The particular embodiments disclosed above are illustrative only, as the invention may be modified and practiced in different but equivalent manners apparent to those skilled in the art having the benefit of the teachings herein. Furthermore, no limitations are intended to the details of construction or design herein shown, other than as described in the claims below. It is therefore evident that the particular embodiments disclosed above may be altered or modified and all such variations are considered within the scope and spirit of the invention. Accordingly, the protection sought herein is as set forth in the claims below.

Claims
  • 1. An aggregate composition for treating a fluid containing one or more contaminants, the composition comprising: an insoluble rare earth-containing compound comprising cerium oxide, wherein the insoluble rare earth-containing compound is adhered to a polymer binder, wherein the aggregate composition is in the form of one of a flowable particulate, granule, bead, pellet, powder, or fiber, and wherein the composition has:i) less than about 15 wt% of the polymer binder; andii) at least about 75 wt% of the insoluble rare earth-containing compound.
  • 2. The aggregate composition of claim 1, wherein the polymer binder is less than about 8% by weight of the aggregate composition.
  • 3. The aggregate composition of claim 1, wherein the polymer binder comprises one or more polymers selected from the group consisting of thermosetting polymers, thermoplastic polymers, elastomeric polymers, cellulosic polymers, and glasses.
  • 4. The aggregate composition of claim 1, wherein the insoluble rare earth-containing compound comprises particulates adhered to an outer surface of the polymer binder and wherein the insoluble rare earth-containing composition is derived by thermal decomposition.
  • 5. The aggregate composition of claim 1, wherein the insoluble rare earth-containing compound further comprises one or both of lanthanum, and praseodymium.
  • 6. The aggregate composition of claim 1, wherein the insoluble rare earth-containing compound comprises cerium oxide in the form of an anhydrous, insoluble rare earth-containing compound.
  • 7. The aggregate composition of claim 1, wherein the insoluble rare earth-containing compound comprises particulates having a mean surface area of at least about 5 m2/g, and wherein the insoluble rare earth-containing compound comprises particulates having a mean particle size of at least about 250 nm.
  • 8. The aggregate composition of claim 1, wherein the insoluble rare earth-containing compound comprises particulates having a mean particle size of at least about 100 nm and wherein the polymer binder is less than about 10% by weight of the composition.
  • 9. The aggregate composition of claim 1, wherein the aggregate composition comprises aggregated particulates having a mean particle size of at least about 0.1 mm.
  • 10. The aggregate composition of claim 1, wherein the aggregate composition has an adsorption capacity for removing arsenic from an aqueous solution of at least about 50 mg of arsenic per gram of the aggregate composition, wherein the aggregate composition comprises aggregated particles having a mean particle size of at least about 0.5 mm and wherein the aggregate composition has a mean surface area of at least about 25 m2/g.
  • 11. The aggregate composition of claim 1, wherein the insoluble rare earth-containing compound comprises two or more insoluble rare earth-containing compounds.
  • 12. The aggregate composition of claim 11, wherein the two or more insoluble rare earth-containing compounds have one or both of differing valence and oxidation states.
  • 13. The aggregate composition of claim 1, wherein the aggregate composition comprises more than about 95% by weight of the insoluble rare earth-containing compound.
  • 14. A composition for treating a fluid containing one or more contaminants, the composition comprises: an aggregate having more than 10.01 wt% of an insoluble rare earth-containing compound comprising cerium oxide derived by thermal decomposition; anda polymeric binder, wherein the insoluble rare earth-containing compound is adhered to the polymeric binder, and wherein the aggregate is in the form of one of a flowable particulate, granule, bead, pellet, powder or fiber.
  • 15. The composition of claim 14, wherein the polymer binder is less than about 8% by weight of the aggregate, wherein the polymer binder comprises one or more polymers selected from the group consisting of thermosetting polymers, thermoplastic polymers, elastomeric polymers, cellulosic polymers, and glasses, and wherein the insoluble rare earth-containing compound comprises particulates adhered to an outer surface of the polymer binder.
  • 16. The composition of claim 14, wherein the insoluble rare earth-containing compound comprises one or both of lanthanum and praseodymium.
  • 17. The composition of claim 14, wherein the insoluble rare earth-containing compound comprises an anhydrous, insoluble rare earth-containing compound.
  • 18. The composition of claim 14, wherein the aggregate further includes a soluble rare earth-containing composition.
  • 19. The composition of claim 14, wherein the aggregate has a mean particle size of at least about 0.1 mm.
  • 20. The composition of claim 14, wherein the aggregate comprises more than about 95% by weight of the insoluble rare earth-containing compound.
  • 21. The composition of claim 14, wherein the insoluble rare earth-containing compound comprises particulates having a mean particle size of at least about 100 nm and wherein the insoluble rare earth-containing compound comprises particulate have a mean surface area of at least about 25 m2/g.
  • 22. An aggregate composition for treating a fluid containing one or more contaminants, the aggregate composition comprising: a polymer binder comprising less than 15% by weight of the aggregate composition;one or more optional soluble rare earth-containing compounds; andan insoluble rare earth-containing compound.
  • 23. The aggregate composition of claim 22, wherein the polymer binder is less than about 10% by weight of the aggregate composition.
  • 24. The aggregate composition of claim 22, wherein the polymer binder comprises one or more polymers selected from the group consisting of polyurethanes, silicones, fluorosilicones, phenolic resins, melamine resins, melamine formaldehyde, urea formaldehyde, nylons and other polyamides, polyethylenes, LDPE, LLDPE, HDPE, polyethylene copolymers, polyolefins, plasticized polyvinylchlorides, unplasticized polyvinylchlorides, fluorocarbon resins, polytetrafluoroethylene, polystyrenes, polypropylenes, cellulosic resins, cellulose acetate butyrates, acrylic resins, polyacrylates, polymethylmethacrylates, thermoplastic blends, thermoplastic grafts, acrylonitrile-butadiene-styrenes, acrylonitrile-styrenes, polycarbonates, polyvinylacetates, ethylene vinyl acetates, polyvinyl alcohols, polyoxymethylene, polyformaldehyde, polyacetals, polyesters, polyethylene terephthalate, polyether ether ketone, phenol-formaldehyde resins, resols, novolacs, elasomers, natural rubbers, synthetic rubbers, styrene-butadiene rubbers, neoprenes, nitrile rubber, butyl rubber, silicones, alkylated chlorosulfonated polyethylene, chlorosulfonated polyethylenes, perfluoroelastomers, polychloroprene, ethylene-propylene-diene terpolymers, chlorinated polyethylene, and fluoroelastomers, wherein the polymer binder is less than about 8% by weight of the aggregate composition.
  • 25. The aggregate composition of claim 22, wherein the insoluble rare earth-containing compound comprises one or more of cerium, lanthanum, or praseodymium, and wherein the insoluble rare earth-containing compound has a mean particle size of at least about 250 nm.
  • 26. The aggregate composition of claim 22, wherein the insoluble rare earth-containing compound comprises cerium oxide has a mean particle size of at least about 500 nm
  • 27. The aggregate composition of claim 22, further comprising one or more flow aids.
  • 28. The aggregate composition of claim 27, wherein the flow aid is selected from the group consisting of inorganic flow aids, ferric sulfate, ferric chloride, ferrous sulfate, aluminum sulfate, sodium aluminate, polyaluminum chloride, aluminum trichloride, silicas, diatomaceous earth, organic flow aids, organic flocculents, cationic polyacrylamides, nonionic polyacrylamides, anionic polyacrylamides, EPI-DMA's, epichlorohydrin-dimethylamines, DADMAC's, polydiallydimethyl-ammonium chlorides, dicyandiamide/formaldehyde polymers, dicyandiamide/amine polymers, and natural guar.
  • 29. The aggregate composition of claim 22, wherein the aggregate composition consists essentially of one or more cerium oxides, wherein the aggregate composition is in the form of a flowable particulate, granule, bead, pellet, powder, fiber or similar form, wherein the aggregate composition has a mean particle size of at least about 0.1 mm, and wherein the aggregate composition has a mean surface area of at least about 25 m2/g.
  • 30. The aggregate composition of claim 22, wherein the insoluble rare earth-containing compound is in the form of one or more of a granule, crystallite, particle or other particulate.
  • 31. The aggregated composition of claim 22, wherein the insoluble rare earth-containing compound includes one or more of lanthanum, cerium, praseodymium, neodymium, promethium, samarium, europium, gadolinium, terbium, dysprosium, holmium erbium, thulium, ytterbium and lutetium and wherein the aggregated composition comprises more than 95% by weight of the insoluble rare earth-containing compound.
  • 32. The aggregated composition of claim 22, wherein the insoluble rare earth-containing compound comprises two or more insoluble rare-earth containing compounds, wherein the two or more insoluble rare earth-containing compound comprises one or more of cerium, lanthanum and praseodymium, wherein the two or more insoluble rare earth-containing compounds comprise the same or different rare earth elements, wherein the same or different rare earth elements have at least one of mixed valence or oxidation states, wherein the aggregate composition has a mean particle size of at least about 0.5 mm, and wherein the aggregate composition has a mean surface area of at least about 70 m2/g.
  • 33. The aggregate composition of claim 22, wherein the insoluble rare earth-containing compound comprises one or more cerium oxides and wherein the one or more soluble rare earth-containing compounds comprise a cerous, ceric or lanthanum-containing compound.
  • 34. The aggregate composition of claim 33, wherein the one or more cerium oxide comprises cerium (IV) oxide (CeO2) and wherein the one or more soluble rare earth-containing compounds is selected from the group consisting of cerium chlorides, cerium nitrates, anhydrous ceric sulfates, lanthanum chlorides, cerous acetates, cerous sulfates, cerous halides, and cerous oxalates.
  • 35. The aggregate composition of claim 22, further including one or both of an inorganic agent and an additive, wherein the inorganic agent is selected from the group consisting of synthetic ion exchange resins, activated carbons, synthetic zeolites, naturally occurring zeolites, minerals, clays, bentonite clays, smectite clays, kaolin clays, dolomite clays, montmorillinite clays, clay derivatives, metal silicate materials, metal silicate minerals, metal phosphates, mineral phosphates, metal oxides, calcium phosphates, aluminum silicates, iron oxides, manganese oxides, and wherein the additive is selected from the group consisting of particle surface modification additives, coupling agents, plasticizers, fillers, expanding agents, fibers, antistatic agents, initiators, suspending agents, photosensitizers, lubricants, wetting agents, surfactants, pigments, dyes, UV stabilizers, and suspending agents.
  • 36. The aggregate composition of claim 22, wherein the binder has a melting temperature, wherein the insoluble rare earth-compound has a sintering temperature and wherein the melting temperature of the polymer does not exceed the sintering temperature of the insoluble rare earth-compound.
  • 37. The aggregate composition of claim 22, wherein the insoluble rare earth-containing compound comprises a matrix of insoluble rare earth-containing particulates adhered to an outer surface of the polymer binder, and wherein the insoluble rare earth-containing compound comprises a matrix of insoluble rare earth-containing particulates embedded in an outer surface of the polymer binder.
  • 38. The aggregate composition of claim 1, wherein the aggregate composition further includes a soluble rare earth-containing composition.
  • 39. The aggregate composition of claim 1, wherein the aggregate composition comprises two or more insoluble rare earth-containing compounds and at least one soluble rare earth-containing compound.
  • 40. The composition of claim 14, wherein the aggregate composition further includes a soluble rare earth-containing composition.
  • 41. The composition of claim 14, wherein the aggregate composition comprises two or more insoluble rare earth-containing compounds and at least one soluble rare earth-containing compound.
  • 42. The composition of claim 14, wherein the insoluble rare earth-containing compound further comprises one or both of lanthanum, and praseodymium.
  • 43. The aggregate composition of claim 22, wherein the insoluble rare earth-containing compound comprises cerium oxide.
  • 44. The aggregate composition of claim 22, wherein the insoluble rare earth-containing compound is an anhydrous, insoluble rare earth-containing compound.
  • 45. The aggregate composition of claim 1, wherein the cerium oxide comprises cerium (IV) oxide.
  • 46. The aggregate composition of claim 1, wherein the cerium oxide comprises cerium (IV) and cerium (III) oxides.
  • 47. The aggregate composition of claim 14, wherein the cerium oxide comprises cerium (IV) oxide.
  • 48. The aggregate composition of claim 14, wherein the cerium oxide comprises cerium (IV) and cerium (III) oxides.
  • 49. The aggregate composition of claim 22, wherein the insoluble rare earth-containing compound comprises cerium (IV) oxide.
  • 50. The aggregate composition of claim 22, wherein the insoluble rare earth-containing compound comprises cerium (IV) and cerium (III) oxides.
US Referenced Citations (540)
Number Name Date Kind
1739840 Kendall Dec 1929 A
2564241 Warf Aug 1951 A
2567661 Ayres Sep 1951 A
2847332 Ramadanoff Aug 1958 A
2872286 Finzel Feb 1959 A
3194629 Dreibelbis et al. Jul 1965 A
3259568 Jordan et al. Jul 1966 A
3337452 Teske et al. Aug 1967 A
3347786 Baer et al. Oct 1967 A
3385915 Hamling May 1968 A
3575853 Gaughan et al. Apr 1971 A
3617569 Daniels et al. Nov 1971 A
3658724 Stiles Apr 1972 A
3692671 Recht et al. Sep 1972 A
3736255 Ghassemi et al. May 1973 A
3761571 Woodhead Sep 1973 A
3768989 Goetzinger et al. Oct 1973 A
3838759 Schmoelz et al. Oct 1974 A
3849537 Allgulin Nov 1974 A
3865728 Abbott et al. Feb 1975 A
3916585 Barks Nov 1975 A
3926807 Evers et al. Dec 1975 A
3956118 Kleber et al. May 1976 A
3965118 Van Rheenen Jun 1976 A
4001375 Longo Jan 1977 A
4046687 Schulze Sep 1977 A
4054516 Izumi et al. Oct 1977 A
4059520 Roller Nov 1977 A
4078058 Fox Mar 1978 A
4080290 Klantschi et al. Mar 1978 A
4088754 Monafo May 1978 A
4094777 Sugier et al. Jun 1978 A
4096064 Du Fresne Jun 1978 A
4101631 Ambrosini et al. Jul 1978 A
4127644 Norman et al. Nov 1978 A
4145282 Bruckenstein Mar 1979 A
4200609 Byrd Apr 1980 A
4230682 Bamberger Oct 1980 A
4231893 Woodhead Nov 1980 A
4251496 Longo et al. Feb 1981 A
4313925 Bamberger Feb 1982 A
4346063 Cahn et al. Aug 1982 A
4386063 Boden May 1983 A
4404197 Fox et al. Sep 1983 A
4436655 Masotti et al. Mar 1984 A
4474580 MacKenzie et al. Oct 1984 A
4474896 Chao Oct 1984 A
4477315 Tomaszewski Oct 1984 A
4498706 Ilardi et al. Feb 1985 A
4507206 Hughes Mar 1985 A
4566975 Allgulin Jan 1986 A
4581229 Petrow Apr 1986 A
4585583 Roberson et al. Apr 1986 A
4588088 Allen May 1986 A
4596659 Nomura et al. Jun 1986 A
4622149 Devuyst et al. Nov 1986 A
4636289 Mani et al. Jan 1987 A
4652054 Copenhafer et al. Mar 1987 A
4661330 Chane-Ching et al. Apr 1987 A
4714694 Wan et al. Dec 1987 A
4738799 Troy Apr 1988 A
4753728 VanderBilt et al. Jun 1988 A
4786483 Audeh Nov 1988 A
4814152 Tan Mar 1989 A
4818483 Culling Apr 1989 A
4828832 De Cuellar et al. May 1989 A
4831519 Morton May 1989 A
4842898 Gradeff Jun 1989 A
4843102 Horton Jun 1989 A
4849223 Pratt Jul 1989 A
4859432 David et al. Aug 1989 A
4861519 Tusa et al. Aug 1989 A
4881176 Kononov Nov 1989 A
4881976 Gradeff Nov 1989 A
4889771 Gradeff et al. Dec 1989 A
4891067 Rappas et al. Jan 1990 A
4902426 Macedo et al. Feb 1990 A
4917875 Moore et al. Apr 1990 A
4920195 Kankare et al. Apr 1990 A
4935146 O'Neill et al. Jun 1990 A
4946592 Galaj et al. Aug 1990 A
4968322 Miyawaki et al. Nov 1990 A
4973501 Gradeff Nov 1990 A
4997425 Shioya et al. Mar 1991 A
4999174 Wilson et al. Mar 1991 A
5004711 Grodek Apr 1991 A
5013534 Dissaux et al. May 1991 A
5017352 Chane-Ching et al. May 1991 A
5024769 Gallup Jun 1991 A
5028736 Girrbach et al. Jul 1991 A
5043072 Hitotsuyanagi et al. Aug 1991 A
5053139 Dodwell et al. Oct 1991 A
5061560 Tajima et al. Oct 1991 A
5064628 Chane-Ching et al. Nov 1991 A
5066758 Honel et al. Nov 1991 A
5080926 Porter et al. Jan 1992 A
5082570 Higgins et al. Jan 1992 A
5104660 Chvapil et al. Apr 1992 A
5116418 Kaliski May 1992 A
5116620 Chvapil et al. May 1992 A
5126116 Krause et al. Jun 1992 A
5130052 Kreh et al. Jul 1992 A
5133948 King et al. Jul 1992 A
5145587 Ishii et al. Sep 1992 A
5152936 Tajima et al. Oct 1992 A
5161385 Schumacher Nov 1992 A
5178768 White, Jr. et al. Jan 1993 A
5192452 Mitsui et al. Mar 1993 A
5207877 Weinberg et al. May 1993 A
5207995 Bosserman May 1993 A
5213779 Kay et al. May 1993 A
5227168 Chvapil et al. Jul 1993 A
5236595 Wang et al. Aug 1993 A
5238488 Wilhelm Aug 1993 A
5248398 Cordani Sep 1993 A
5260066 Wood et al. Nov 1993 A
5281253 Thompson Jan 1994 A
5326737 Kay et al. Jul 1994 A
5328669 Han et al. Jul 1994 A
5330770 Kuno Jul 1994 A
5338460 Yen Aug 1994 A
5344479 Kerfoot et al. Sep 1994 A
5352365 Fuller Oct 1994 A
5356437 Pedersen et al. Oct 1994 A
5358643 Mcclintock Oct 1994 A
5368703 Brewster Nov 1994 A
5389352 Wang Feb 1995 A
5403495 Kust et al. Apr 1995 A
5409522 Durham et al. Apr 1995 A
5422489 Bhargava Jun 1995 A
5422907 Bhargava Jun 1995 A
5433931 Bosserman Jul 1995 A
5446286 Bhargava Aug 1995 A
5455489 Bhargava Oct 1995 A
5500198 Liu et al. Mar 1996 A
5505766 Chang Apr 1996 A
5529811 Sinko Jun 1996 A
5545604 Demmel Aug 1996 A
5551976 Allen Sep 1996 A
5556545 Volchek et al. Sep 1996 A
5575915 Nakamura et al. Nov 1996 A
5575919 Santina Nov 1996 A
5580535 Hoke et al. Dec 1996 A
5599851 Jin et al. Feb 1997 A
5603838 Misra et al. Feb 1997 A
5611934 Shepperd, III et al. Mar 1997 A
5618406 Demmel Apr 1997 A
5637258 Goldburt et al. Jun 1997 A
5649894 White et al. Jul 1997 A
5660802 Archer et al. Aug 1997 A
5683953 Mills Nov 1997 A
5688378 Khoe et al. Nov 1997 A
5689038 Bartram et al. Nov 1997 A
5698212 Hagiwara Dec 1997 A
5702592 Suri et al. Dec 1997 A
5711930 Albers et al. Jan 1998 A
5712218 Chopin et al. Jan 1998 A
5712219 Klabunde et al. Jan 1998 A
5728404 Von Rheinbaben et al. Mar 1998 A
5730995 Shirono et al. Mar 1998 A
5759855 Pierschbacher et al. Jun 1998 A
5759939 Klabunde et al. Jun 1998 A
5783057 Tomita et al. Jul 1998 A
5795836 Jin et al. Aug 1998 A
5820966 Krause et al. Oct 1998 A
5833841 Koslowsky Nov 1998 A
5859064 Cronce Jan 1999 A
5876610 Clack et al. Mar 1999 A
5897675 Mangold et al. Apr 1999 A
5897781 Dourdeville Apr 1999 A
5897784 Mills Apr 1999 A
5910253 Fuerstenau et al. Jun 1999 A
5914287 Saito Jun 1999 A
5914436 Klabunde et al. Jun 1999 A
5918555 Winegar Jul 1999 A
5922926 Back et al. Jul 1999 A
5928504 Hembre et al. Jul 1999 A
5938837 Hanawa et al. Aug 1999 A
5939087 Hagiwara Aug 1999 A
5952665 Bhargava Sep 1999 A
5976383 Guess et al. Nov 1999 A
5990373 Klabunde Nov 1999 A
5994260 Bonneau Nov 1999 A
6001152 Sinha Dec 1999 A
6001157 Nogami Dec 1999 A
6017553 Burrell et al. Jan 2000 A
6030537 Shaniuk et al. Feb 2000 A
6036886 Chhabra et al. Mar 2000 A
6045925 Klabunde et al. Apr 2000 A
6048821 Demmel et al. Apr 2000 A
6057488 Koper et al. May 2000 A
6087294 Klabunde et al. Jul 2000 A
6093236 Klabunde et al. Jul 2000 A
6093325 Stone Jul 2000 A
6093328 Santina Jul 2000 A
6099819 Srinivas et al. Aug 2000 A
6114038 Castro et al. Sep 2000 A
6123323 Yoneda et al. Sep 2000 A
6132623 Nikolaidis et al. Oct 2000 A
6136749 Gadkaree et al. Oct 2000 A
6143318 Gilchrist et al. Nov 2000 A
6146539 Mills Nov 2000 A
6177015 Blakey et al. Jan 2001 B1
6180016 Johnston et al. Jan 2001 B1
6187192 Johnston et al. Feb 2001 B1
6187205 Martin et al. Feb 2001 B1
6197201 Misra et al. Mar 2001 B1
6197204 Heskett Mar 2001 B1
6200482 Winchester et al. Mar 2001 B1
6203709 Min et al. Mar 2001 B1
6214238 Gallup Apr 2001 B1
6221118 Yoshida et al. Apr 2001 B1
6221602 Barbera-Guillem et al. Apr 2001 B1
6221903 Courchesne Apr 2001 B1
6224898 Balogh et al. May 2001 B1
6238566 Yoshida et al. May 2001 B1
6238686 Burrell et al. May 2001 B1
6248605 Harkonen et al. Jun 2001 B1
6258334 Gadkaree et al. Jul 2001 B1
6264841 Tudor Jul 2001 B1
6294006 Andou Sep 2001 B1
6299851 Li et al. Oct 2001 B1
6300640 Bhargava et al. Oct 2001 B1
6312604 Denkewicz et al. Nov 2001 B1
6319108 Adefris et al. Nov 2001 B1
6326326 Feng et al. Dec 2001 B1
6328779 He et al. Dec 2001 B1
6338800 Kulperger et al. Jan 2002 B1
6341567 Robertson et al. Jan 2002 B1
6342163 DeLonge et al. Jan 2002 B1
6350383 Douglas Feb 2002 B1
6351932 Hummel Mar 2002 B1
6361824 Yekimov et al. Mar 2002 B1
6368510 Friot Apr 2002 B2
6372003 Kasai et al. Apr 2002 B1
6375834 Guess et al. Apr 2002 B1
6383273 Kepner et al. May 2002 B1
6383395 Clarke et al. May 2002 B1
6391207 Cluyse May 2002 B1
6391869 Parks et al. May 2002 B1
6395659 Seto et al. May 2002 B2
6395736 Parks et al. May 2002 B1
6403653 Hobson et al. Jun 2002 B1
6406676 Sundkvist Jun 2002 B1
6410603 Hobson et al. Jun 2002 B1
6417423 Koper et al. Jul 2002 B1
6420434 Braue et al. Jul 2002 B1
6428705 Allen et al. Aug 2002 B1
6440300 Randall et al. Aug 2002 B1
6444143 Bawendi et al. Sep 2002 B2
6452184 Taskar et al. Sep 2002 B1
6460535 Nisewander et al. Oct 2002 B1
6461535 de Esparza Oct 2002 B1
6468499 Balachandran et al. Oct 2002 B1
6475451 Leppin et al. Nov 2002 B1
6524487 Kulperger et al. Feb 2003 B2
6524540 Heinig Feb 2003 B1
6528451 Brezny et al. Mar 2003 B2
6536672 Outwater Mar 2003 B1
6537382 Bartram et al. Mar 2003 B1
6542487 Ishii et al. Apr 2003 B1
6542540 Leung et al. Apr 2003 B1
6551514 Misra et al. Apr 2003 B1
6562092 Ito et al. May 2003 B1
6562403 Klabunde et al. May 2003 B2
6569224 Kerfoot et al. May 2003 B2
6569393 Hoke et al. May 2003 B1
6569490 Yadav et al. May 2003 B2
6572672 Yadav et al. Jun 2003 B2
6576092 Granite et al. Jun 2003 B2
6585787 Yamasaki et al. Jul 2003 B2
6589496 Yabe et al. Jul 2003 B1
6599428 Douglas Jul 2003 B1
6599429 Azizian Jul 2003 B1
6602111 Fujie et al. Aug 2003 B1
6602671 Bawendi et al. Aug 2003 B1
6610264 Buchanan et al. Aug 2003 B1
6613230 Krulik et al. Sep 2003 B2
6623642 Robertson Sep 2003 B2
6627632 Parks et al. Sep 2003 B2
6653519 Koper et al. Nov 2003 B2
6666903 Green Dec 2003 B1
6680211 Barbera-Guillem et al. Jan 2004 B2
6689178 Ito et al. Feb 2004 B2
6706082 Ota et al. Mar 2004 B2
6706195 Jensen et al. Mar 2004 B2
6716895 Terry Apr 2004 B1
6719828 Lovell et al. Apr 2004 B1
6723349 Hill et al. Apr 2004 B1
6740141 Espin et al. May 2004 B2
6770483 Lyon Aug 2004 B2
6774361 Bawendi et al. Aug 2004 B2
6780332 Shiau et al. Aug 2004 B2
6790363 Vempati Sep 2004 B2
6790420 Breen et al. Sep 2004 B2
6790521 Taketomi et al. Sep 2004 B1
6800204 Harck et al. Oct 2004 B2
6808692 Oehr Oct 2004 B2
6821414 Johnson et al. Nov 2004 B1
6821434 Moore et al. Nov 2004 B1
6824690 Zhao et al. Nov 2004 B1
6827766 Carnes et al. Dec 2004 B2
6833123 Huang et al. Dec 2004 B2
6843617 Chowdhury et al. Jan 2005 B2
6843919 Klabunde et al. Jan 2005 B2
6843923 Morton Jan 2005 B2
6846432 Mills Jan 2005 B2
6849187 Shaniuk Feb 2005 B2
6852903 Brown et al. Feb 2005 B1
6855665 Blake et al. Feb 2005 B1
6858147 Dukhin et al. Feb 2005 B2
6860924 Rajagopalan et al. Mar 2005 B2
6861002 Hughes Mar 2005 B2
6862825 Lowndes Mar 2005 B1
6863825 Witham et al. Mar 2005 B2
6864213 Labarge et al. Mar 2005 B2
6881424 Kemp et al. Apr 2005 B1
6881766 Hain Apr 2005 B2
6883825 Schneider Apr 2005 B2
6887302 Rajagopalan et al. May 2005 B2
6887566 Hung et al. May 2005 B1
6896809 Qian et al. May 2005 B2
6901684 Ito et al. Jun 2005 B2
6905527 Ito et al. Jun 2005 B2
6905698 Aldcroft et al. Jun 2005 B1
6908560 Guter Jun 2005 B2
6908570 Green Jun 2005 B2
6908628 Herruzo Jun 2005 B2
6914033 Gislason et al. Jul 2005 B2
6914034 Vo Jul 2005 B2
6919029 Meng et al. Jul 2005 B2
6921739 Smith et al. Jul 2005 B2
6927501 Baarman et al. Aug 2005 B2
6942840 Broderick Sep 2005 B1
6946076 Mills Sep 2005 B2
6946578 Nakano et al. Sep 2005 B2
6957743 Johnston et al. Oct 2005 B2
6960329 Sellakumar Nov 2005 B2
6974564 Biermann et al. Dec 2005 B2
6977039 Knoll et al. Dec 2005 B2
6986798 Bessho et al. Jan 2006 B2
6987129 Mak et al. Jan 2006 B2
6998080 Stadermann et al. Feb 2006 B2
7008559 Chen Mar 2006 B2
7014782 D'Emidio et al. Mar 2006 B2
7025800 Campbell et al. Apr 2006 B2
7029516 Campbell et al. Apr 2006 B2
7033419 Granite et al. Apr 2006 B1
RE39098 Klabunde et al. May 2006 E
7037480 Bhinde May 2006 B2
7048853 Witham et al. May 2006 B2
7048860 Oishi May 2006 B2
7049382 Haftka et al. May 2006 B2
7056454 Fujino Jun 2006 B2
7060233 Srinivas et al. Jun 2006 B1
7067294 Singh et al. Jun 2006 B2
7074336 Teter et al. Jul 2006 B1
7078071 Taketomi et al. Jul 2006 B2
7081428 Thampi Jul 2006 B1
7083730 Davis Aug 2006 B2
7094383 Wang et al. Aug 2006 B2
7101415 Torres et al. Sep 2006 B2
7101493 Colucci Sep 2006 B2
7112237 Zeller et al. Sep 2006 B2
7129684 Park Oct 2006 B2
7141227 Chan Nov 2006 B2
7156888 Mochizuki Jan 2007 B2
7156994 Archer Jan 2007 B1
7160505 Belbachir et al. Jan 2007 B2
7179849 Terry Feb 2007 B2
7183235 Lovell et al. Feb 2007 B2
7186671 Smith et al. Mar 2007 B2
7192602 Fechner et al. Mar 2007 B2
7211320 Cooper et May 2007 B1
7214836 Brown et al. May 2007 B2
7241629 Dejneka et al. Jul 2007 B2
7250174 Lee et al. Jul 2007 B2
7252694 Woo et al. Aug 2007 B2
7252769 Dickinson Aug 2007 B2
7256049 Bennett et al. Aug 2007 B2
7276640 Mulukutla et al. Oct 2007 B2
7279129 Lanz et al. Oct 2007 B2
7282153 Barrett et al. Oct 2007 B2
7291272 Bourke et al. Nov 2007 B2
7291315 Obee et al. Nov 2007 B2
7297263 Nelson et al. Nov 2007 B2
7297656 Zhang et al. Nov 2007 B2
7300587 Smith et al. Nov 2007 B2
7300589 Witham et al. Nov 2007 B2
7311842 Kim Dec 2007 B2
7329356 Brady Feb 2008 B2
7329359 Roark Feb 2008 B2
7335622 Koyanaka et al. Feb 2008 B2
7335808 Koper et al. Feb 2008 B2
7338603 McNew et al. Mar 2008 B1
7341618 Bayer et al. Mar 2008 B2
7341667 Kennard et al. Mar 2008 B2
7341977 Klabunde et al. Mar 2008 B2
7361279 Hernandez Apr 2008 B2
7368388 Small et al. May 2008 B2
7368412 Tranter et al. May 2008 B2
7378372 Sylvester May 2008 B2
7422759 Kepner et al. Sep 2008 B2
7429330 Vo et al. Sep 2008 B2
7431758 Ota et al. Oct 2008 B2
7438828 Young Oct 2008 B2
7445718 Misra et al. Nov 2008 B2
7459086 Gaid Dec 2008 B2
7468413 Yokota et al. Dec 2008 B2
7473474 Toreki et al. Jan 2009 B2
7476311 Litz et al. Jan 2009 B2
7481939 Haley Jan 2009 B2
7498005 Yadav Mar 2009 B2
7534287 Zeller et al. May 2009 B2
7534453 Rzigalinski et al. May 2009 B1
7560023 Miyazawa et al. Jul 2009 B2
7566393 Klabunde et al. Jul 2009 B2
7572416 Alward et al. Aug 2009 B2
7588744 Sylvester Sep 2009 B1
7588782 Moerck et al. Sep 2009 B2
7591952 Young Sep 2009 B2
7611620 Carson et al. Nov 2009 B2
7645540 Boone et al. Jan 2010 B2
7661483 Mulukutla et al. Feb 2010 B2
7745509 Burton et al. Jun 2010 B2
7820100 Garfield et al. Oct 2010 B2
20010009831 Schink et al. Jul 2001 A1
20010012856 Parks et al. Aug 2001 A1
20020003116 Golden Jan 2002 A1
20020005382 Kulperger et al. Jan 2002 A1
20020005383 Voute et al. Jan 2002 A1
20020044901 Wildon et al. Apr 2002 A1
20020066702 Liu Jun 2002 A1
20020072522 Parks et al. Jun 2002 A1
20020187990 Parks et al. Dec 2002 A1
20020198136 Mak et al. Dec 2002 A1
20030015467 Johnston et al. Jan 2003 A1
20030133990 Hursey et al. Jul 2003 A1
20030149406 Martineau et al. Aug 2003 A1
20030156981 Mills Aug 2003 A1
20030180213 Carnes et al. Sep 2003 A1
20030203977 Klabunde et al. Oct 2003 A1
20030207949 Klabunde et al. Nov 2003 A1
20030215378 Zhou et al. Nov 2003 A1
20040029715 Schindler et al. Feb 2004 A1
20040031764 Heinig Feb 2004 A1
20040043914 Kaziska et al. Mar 2004 A1
20040050795 Park et al. Mar 2004 A1
20040091417 Yadav May 2004 A1
20040104377 Phelps et al. Jun 2004 A1
20040109853 McDaniel Jun 2004 A1
20040202703 Meyer-Ingold et al. Oct 2004 A1
20040230086 Okun et al. Nov 2004 A1
20050008861 Yadav et al. Jan 2005 A1
20050058689 McDaniel Mar 2005 A1
20050067347 Vanhulle et al. Mar 2005 A1
20050069464 Obee et al. Mar 2005 A1
20050079415 Boone et al. Apr 2005 A1
20050084755 Boone et al. Apr 2005 A1
20050098503 Kim May 2005 A1
20050126338 Yadav Jun 2005 A1
20050126430 Lightner, Jr. et al. Jun 2005 A1
20050136486 Haushalter Jun 2005 A1
20050159307 Okun et al. Jul 2005 A1
20050230659 Hampden-Smith et al. Oct 2005 A1
20050257724 Guinther et al. Nov 2005 A1
20050271941 Bushong et al. Dec 2005 A1
20060000763 Rinker et al. Jan 2006 A1
20060018954 Kuttler Jan 2006 A1
20060030622 Mak et al. Feb 2006 A1
20060049091 Cheetham et al. Mar 2006 A1
20060062831 Meyer-Ingold et al. Mar 2006 A1
20060070947 Conrad Apr 2006 A1
20060120930 Mizukami Jun 2006 A1
20060178609 Horn et al. Aug 2006 A1
20060198883 Parks et al. Sep 2006 A1
20060199301 Basheer et al. Sep 2006 A1
20060199733 Grier et al. Sep 2006 A1
20060224237 Furst et al. Oct 2006 A1
20060228275 Rutman Oct 2006 A1
20060237369 Kirts et al. Oct 2006 A1
20060246149 Buchholz et al. Nov 2006 A1
20060254930 Martinie et al. Nov 2006 A1
20060257728 Mortensen et al. Nov 2006 A1
20060275564 Grah et al. Dec 2006 A1
20070000836 Elefritz et al. Jan 2007 A1
20070012631 Coffey et al. Jan 2007 A1
20070017871 Reddy et al. Jan 2007 A1
20070065491 Huey et al. Mar 2007 A1
20070080115 Sylvester Apr 2007 A1
20070081931 Cho et al. Apr 2007 A1
20070114179 Badger May 2007 A1
20070122327 Yang et al. May 2007 A1
20070128424 Omori et al. Jun 2007 A1
20070134307 Xiao et al. Jun 2007 A1
20070142783 Huey et al. Jun 2007 A1
20070149405 Spitler et al. Jun 2007 A1
20070158251 Chau Jul 2007 A1
20070167971 Huey et al. Jul 2007 A1
20070169626 Sullivan Jul 2007 A1
20070286796 Koper et al. Dec 2007 A1
20070298085 Lestage et al. Dec 2007 A1
20080050440 Wakamura et al. Feb 2008 A1
20080058206 Misra et al. Mar 2008 A1
20080058689 Holloway et al. Mar 2008 A1
20080081120 Van Ooij et al. Apr 2008 A1
20080090138 Vu et al. Apr 2008 A1
20080093580 Witham et al. Apr 2008 A1
20080097271 Lo et al. Apr 2008 A1
20080102136 Koper et al. May 2008 A1
20080125686 Lo May 2008 A1
20080156734 Burba et al. Jul 2008 A1
20080199539 Baker et al. Aug 2008 A1
20080254146 Huey et al. Oct 2008 A1
20080254147 Huey et al. Oct 2008 A1
20080262285 Black et al. Oct 2008 A1
20080264300 Sato et al. Oct 2008 A1
20080302267 Defalco Dec 2008 A1
20080311311 Khan et al. Dec 2008 A1
20090001011 Knipmeyer et al. Jan 2009 A1
20090011240 Lenz et al. Jan 2009 A1
20090011930 Hagemeyer Jan 2009 A1
20090012204 Drechsler et al. Jan 2009 A1
20090069844 Green et al. Mar 2009 A1
20090098016 Koper et al. Apr 2009 A1
20090101588 Misra et al. Apr 2009 A1
20090101837 Kourtakis et al. Apr 2009 A1
20090107919 Burba et al. Apr 2009 A1
20090107925 Burba et al. Apr 2009 A1
20090108777 Hyde et al. Apr 2009 A1
20090111289 Vinther Apr 2009 A1
20090112043 Burba et al. Apr 2009 A1
20090120802 Ciampi et al. May 2009 A1
20090130169 Bernstein May 2009 A1
20090206042 Landau et al. Aug 2009 A1
20090264574 Van Ooij et al. Oct 2009 A1
20090299253 Hursey Dec 2009 A1
20100003296 Cheng et al. Jan 2010 A1
20100042206 Yadav et al. Feb 2010 A1
20100055456 Perera et al. Mar 2010 A1
Foreign Referenced Citations (80)
Number Date Country
2396510 Feb 2003 CA
1248486 Mar 2000 CN
0191893 Aug 1986 EP
0541158 May 1993 EP
0597173 May 1994 EP
0812619 Dec 1997 EP
0939431 Jan 1999 EP
1201607 Feb 2002 EP
1080144 Aug 2002 EP
1452229 Sep 2004 EP
1071500 Feb 2005 EP
1870150 Dec 2007 EP
1992394 Nov 2008 EP
2161067 Mar 2010 EP
2177252 Apr 2010 EP
1447264 Aug 1976 GB
2426469 Nov 2006 GB
1151917 Jun 1989 JP
H2-17220 Apr 1990 JP
6-207561 Jul 1994 JP
10165948 Jun 1998 JP
11090413 Apr 1999 JP
11302684 Nov 1999 JP
11-302684 Nov 1999 JP
2000-024647 Jan 2000 JP
2000024647 Jan 2000 JP
2002205062 Jul 2002 JP
2002-282686 Oct 2002 JP
2002349234 Dec 2002 JP
2004050069 Feb 2004 JP
2004057870 Feb 2004 JP
2004305915 Nov 2004 JP
2004330012 Nov 2004 JP
2005-23373 Jan 2005 JP
2005-028312 Feb 2005 JP
2005028312 Feb 2005 JP
2005048181 Feb 2005 JP
2005-288363 Oct 2005 JP
2005288363 Oct 2005 JP
2006-320847 Nov 2006 JP
2006320847 Nov 2006 JP
07081932 Mar 2007 JP
2010-083741 Apr 2010 JP
2136607 Sep 1999 RU
2178599 Jan 2002 RU
663291 May 1979 SU
1766848 Oct 1992 SU
WO 9511195 Apr 1995 WO
WO 9712672 Apr 1997 WO
WO 9807493 Feb 1998 WO
WO 9928239 Jun 1999 WO
WO 0024680 May 2000 WO
WO 0132799 May 2001 WO
WO 0132820 May 2001 WO
WO 0178506 Oct 2001 WO
WO 03092748 Nov 2003 WO
WO 2004076770 Sep 2004 WO
2004096433 Nov 2004 WO
WO 2005028707 Mar 2005 WO
WO 2005042130 May 2005 WO
WO 2005056175 Jun 2005 WO
WO 2005075000 Aug 2005 WO
WO 2005081722 Sep 2005 WO
WO 2006011764 Feb 2006 WO
WO 2006044784 Apr 2006 WO
WO 2006047613 May 2006 WO
WO 2006070153 Jul 2006 WO
WO 2006102008 Sep 2006 WO
WO 2006117424 Nov 2006 WO
WO 2007011877 Jan 2007 WO
WO 2007041553 Apr 2007 WO
WO 2007120910 Oct 2007 WO
WO 2008151173 Dec 2008 WO
WO 2009064845 May 2009 WO
WO 2009142823 Nov 2009 WO
WO 2010010569 Jan 2010 WO
WO 2010010570 Jan 2010 WO
WO 2010010571 Jan 2010 WO
WO 2010010574 Jan 2010 WO
WO 2010019934 Feb 2010 WO
Related Publications (1)
Number Date Country
20090111689 A1 Apr 2009 US